More on HROW

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-145.8% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Harrow Health (NQ:HROW)
Delayed: 46.65 +1.77 (3.94%)
Prev. Close $44.88  
Open$44.43 
52 Wk High$ 
52 Wk Low$ 
Day High$47.50 
Day Low$44.04 
P/E N/A  
EPS$ 
Volume827,722 


Jul 1, 2026 07:00 AM Samsung Bioepis relaunches eye disease biosimilar with Harrow in the US
Jul 1, 2026 07:00 AM Harrow launches BYOOVIZ biosimilar for retinal diseases in U.S.
Jul 1, 2026 07:00 AM Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Jul 1, 2026 07:00 AM Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
Jun 22, 2026 07:51 PM Form 4 HARROW, INC. For: Jun 18 Filed by: Sternberg Perry J.
Jun 22, 2026 07:51 PM Form 4 HARROW, INC. For: Jun 18 Filed by: Graves Adrienne L
Jun 22, 2026 07:51 PM Form 4 HARROW, INC. For: Jun 18 Filed by: SILVERNAIL LAUREN P
Jun 22, 2026 07:30 AM Form 8-K HARROW, INC. For: Jun 18
Jun 10, 2026 07:01 AM Harrow re-launches VERKAZIA eye drops for pediatric eye condition
Jun 10, 2026 07:00 AM Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
View All Articles

Entities mentioned with HROW

View All Entities